COO vs. RPRX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at COO and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | COO | RPRX |
|---|---|---|
| Company Name | The Cooper Companies, Inc. | Royalty Pharma plc |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 14.41 billion USD | 23.01 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | January 21, 1983 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of COO and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | COO | RPRX |
|---|---|---|
| 5-Day Price Return | 1.99% | 1.61% |
| 13-Week Price Return | -1.54% | 7.73% |
| 26-Week Price Return | -11.78% | 19.32% |
| 52-Week Price Return | -29.20% | 51.49% |
| Month-to-Date Return | 3.18% | 4.32% |
| Year-to-Date Return | -21.54% | 53.51% |
| 10-Day Avg. Volume | 1.91M | 5.43M |
| 3-Month Avg. Volume | 2.54M | 3.75M |
| 3-Month Volatility | 37.85% | 26.39% |
| Beta | 1.03 | 0.42 |
Profitability
Return on Equity (TTM)
COO
4.97%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
COO’s Return on Equity of 4.97% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
RPRX
11.59%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
RPRX’s Return on Equity of 11.59% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
COO
10.08%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
COO’s Net Profit Margin of 10.08% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
RPRX
32.55%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 32.55% places RPRX in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
COO
18.31%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
COO’s Operating Profit Margin of 18.31% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
RPRX
65.22%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
RPRX’s Operating Profit Margin of 65.22% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | COO | RPRX |
|---|---|---|
| Return on Equity (TTM) | 4.97% | 11.59% |
| Return on Assets (TTM) | 3.31% | 4.16% |
| Net Profit Margin (TTM) | 10.08% | 32.55% |
| Operating Profit Margin (TTM) | 18.31% | 65.22% |
| Gross Profit Margin (TTM) | 66.96% | -- |
Financial Strength
Current Ratio (MRQ)
COO
2.12
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
COO’s Current Ratio of 2.12 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
RPRX
3.48
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
RPRX’s Current Ratio of 3.48 is in the upper quartile for the Pharmaceuticals industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
COO
0.30
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
COO’s Debt-to-Equity Ratio of 0.30 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RPRX
1.39
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.39. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
COO
5.87
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
COO’s Interest Coverage Ratio of 5.87 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | COO | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 2.12 | 3.48 |
| Quick Ratio (MRQ) | 0.91 | 3.48 |
| Debt-to-Equity Ratio (MRQ) | 0.30 | 1.39 |
| Interest Coverage Ratio (TTM) | 5.87 | 4.70 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
COO
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
COO currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RPRX
1.67%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.67% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
COO
1.63%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
COO’s Dividend Payout Ratio of 1.63% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RPRX
49.36%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 49.36% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | COO | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.67% |
| Dividend Payout Ratio (TTM) | 1.63% | 49.36% |
Valuation
Price-to-Earnings Ratio (TTM)
COO
35.16
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
COO’s P/E Ratio of 35.16 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RPRX
29.52
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
RPRX’s P/E Ratio of 29.52 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
COO
3.54
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
COO’s P/S Ratio of 3.54 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RPRX
9.61
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
With a P/S Ratio of 9.61, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
COO
1.69
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
COO’s P/B Ratio of 1.69 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
RPRX
3.21
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
RPRX’s P/B Ratio of 3.21 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | COO | RPRX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 35.16 | 29.52 |
| Price-to-Sales Ratio (TTM) | 3.54 | 9.61 |
| Price-to-Book Ratio (MRQ) | 1.69 | 3.21 |
| Price-to-Free Cash Flow Ratio (TTM) | 34.81 | 18.76 |